These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

484 related items for PubMed ID: 30875761

  • 1. Uncovering the Neuroprotective Mechanisms of Curcumin on Transthyretin Amyloidosis.
    Ferreira N, Saraiva MJ, Almeida MR.
    Int J Mol Sci; 2019 Mar 14; 20(6):. PubMed ID: 30875761
    [Abstract] [Full Text] [Related]

  • 2. Tolcapone, a potent aggregation inhibitor for the treatment of familial leptomeningeal amyloidosis.
    Pinheiro F, Varejão N, Esperante S, Santos J, Velázquez-Campoy A, Reverter D, Pallarès I, Ventura S.
    FEBS J; 2021 Jan 14; 288(1):310-324. PubMed ID: 32324953
    [Abstract] [Full Text] [Related]

  • 3. Transthyretin (ATTR) amyloidosis: clinical spectrum, molecular pathogenesis and disease-modifying treatments.
    Sekijima Y.
    J Neurol Neurosurg Psychiatry; 2015 Sep 14; 86(9):1036-43. PubMed ID: 25604431
    [Abstract] [Full Text] [Related]

  • 4. Curcumin could reduce the monomer of TTR with Tyr114Cys mutation via autophagy in cell model of familial amyloid polyneuropathy.
    Li H, Zhang Y, Cao L, Xiong R, Zhang B, Wu L, Zhao Z, Chen SD.
    Drug Des Devel Ther; 2014 Sep 14; 8():2121-8. PubMed ID: 25382970
    [Abstract] [Full Text] [Related]

  • 5. Disease-associated mutations impacting BC-loop flexibility trigger long-range transthyretin tetramer destabilization and aggregation.
    Esperante SA, Varejāo N, Pinheiro F, Sant'Anna R, Luque-Ortega JR, Alfonso C, Sora V, Papaleo E, Rivas G, Reverter D, Ventura S.
    J Biol Chem; 2021 Sep 14; 297(3):101039. PubMed ID: 34343569
    [Abstract] [Full Text] [Related]

  • 6. Transthyretin Misfolding, A Fatal Structural Pathogenesis Mechanism.
    Si JB, Kim B, Kim JH.
    Int J Mol Sci; 2021 Apr 23; 22(9):. PubMed ID: 33922648
    [Abstract] [Full Text] [Related]

  • 7. Uncovering the Mechanism of Aggregation of Human Transthyretin.
    Saelices L, Johnson LM, Liang WY, Sawaya MR, Cascio D, Ruchala P, Whitelegge J, Jiang L, Riek R, Eisenberg DS.
    J Biol Chem; 2015 Nov 27; 290(48):28932-43. PubMed ID: 26459562
    [Abstract] [Full Text] [Related]

  • 8. Dietary curcumin counteracts extracellular transthyretin deposition: insights on the mechanism of amyloid inhibition.
    Ferreira N, Santos SA, Domingues MR, Saraiva MJ, Almeida MR.
    Biochim Biophys Acta; 2013 Jan 27; 1832(1):39-45. PubMed ID: 23069388
    [Abstract] [Full Text] [Related]

  • 9. Novel conformation-specific monoclonal antibodies against amyloidogenic forms of transthyretin.
    Higaki JN, Chakrabartty A, Galant NJ, Hadley KC, Hammerson B, Nijjar T, Torres R, Tapia JR, Salmans J, Barbour R, Tam SJ, Flanagan K, Zago W, Kinney GG.
    Amyloid; 2016 Jun 27; 23(2):86-97. PubMed ID: 26981744
    [Abstract] [Full Text] [Related]

  • 10. A Brief Journey through Protein Misfolding in Transthyretin Amyloidosis (ATTR Amyloidosis).
    Gonzalez-Duarte A, Ulloa-Aguirre A.
    Int J Mol Sci; 2021 Dec 06; 22(23):. PubMed ID: 34884963
    [Abstract] [Full Text] [Related]

  • 11. Tafamidis: a selective transthyretin stabilizer to treat wild-type ATTR amyloidosis and hereditary ATTR amyloidosis with cardiomyopathy.
    Paton DM.
    Drugs Today (Barc); 2019 Dec 06; 55(12):727-734. PubMed ID: 31942875
    [Abstract] [Full Text] [Related]

  • 12. Impairment of autophagy by TTR V30M aggregates: in vivo reversal by TUDCA and curcumin.
    Teixeira CA, Almeida Mdo R, Saraiva MJ.
    Clin Sci (Lond); 2016 Sep 01; 130(18):1665-75. PubMed ID: 27382986
    [Abstract] [Full Text] [Related]

  • 13. Trapping the monomer of a non-amyloidogenic variant of transthyretin: exploring its possible use as a therapeutic strategy against transthyretin amyloidogenic diseases.
    Palhano FL, Leme LP, Busnardo RG, Foguel D.
    J Biol Chem; 2009 Jan 16; 284(3):1443-53. PubMed ID: 18984591
    [Abstract] [Full Text] [Related]

  • 14. Pathological, biochemical, and biophysical characteristics of the transthyretin variant Y114H (p.Y134H) explain its very mild clinical phenotype.
    Sekijima Y, Campos RI, Hammarström P, Nilsson KP, Yoshinaga T, Nagamatsu K, Yazaki M, Kametani F, Ikeda S.
    J Peripher Nerv Syst; 2015 Dec 16; 20(4):372-9. PubMed ID: 26306725
    [Abstract] [Full Text] [Related]

  • 15. Curcumin: A multi-target disease-modifying agent for late-stage transthyretin amyloidosis.
    Ferreira N, Gonçalves NP, Saraiva MJ, Almeida MR.
    Sci Rep; 2016 May 20; 6():26623. PubMed ID: 27197872
    [Abstract] [Full Text] [Related]

  • 16. [Transthyretin-related amyloidotic cardiomyopathy: looking for the etiological treatment].
    Longhi S, Gagliardi C, Milandri A, Manuzzi L, Rapezzi C.
    G Ital Cardiol (Rome); 2014 May 20; 15(5):293-300. PubMed ID: 25002169
    [Abstract] [Full Text] [Related]

  • 17. Identification of the interfacial regions in misfolded transthyretin oligomers.
    Dasari AKR, Coats MF, Ali AB, Lim KH.
    Biochim Biophys Acta Proteins Proteom; 2024 Sep 01; 1872(5):141027. PubMed ID: 38796131
    [Abstract] [Full Text] [Related]

  • 18. A Comprehensive Review on Chemistry and Biology of Tafamidis in Transthyretin Amyloidosis.
    Patil MB, Ghode P, Joshi P.
    Mini Rev Med Chem; 2024 Sep 01; 24(6):571-587. PubMed ID: 37828667
    [Abstract] [Full Text] [Related]

  • 19. Tafamidis for transthyretin amyloidosis.
    de Lartigue J.
    Drugs Today (Barc); 2012 May 01; 48(5):331-7. PubMed ID: 22645721
    [Abstract] [Full Text] [Related]

  • 20. The importance of a gatekeeper residue on the aggregation of transthyretin: implications for transthyretin-related amyloidoses.
    Sant'Anna R, Braga C, Varejão N, Pimenta KM, Graña-Montes R, Alves A, Cortines J, Cordeiro Y, Ventura S, Foguel D.
    J Biol Chem; 2014 Oct 10; 289(41):28324-37. PubMed ID: 25086037
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 25.